☆ 4.5 Article

Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer

BREAST CANCER RESEARCH AND TREATMENT (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

N. Harbeck et al.

Summary: Adjuvant abemaciclib combined with endocrine therapy significantly improved invasive disease-free survival in patients with early breast cancer, with an acceptable safety profile. Ki-67 index was prognostic but did not affect the benefits of abemaciclib. The robust treatment benefit of abemaciclib extended beyond the planned 2-year treatment period.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic

Ko Un Park et al.

Summary: During the COVID-19 pandemic in the US, physicians showed a preference for neoadjuvant endocrine therapy (NET) for ER + BC patients, with an increase in the favor of axillary lymph node dissection (ALND) in cases of low volume metastatic axillary disease as the duration of NET extended.

BREAST CANCER RESEARCH AND TREATMENT (2021)

Add to Collection

Article Medicine, General & Internal

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

Kevin Kalinsky et al.

Summary: The study showed that among premenopausal women with hormone-receptor-positive, HER2-negative breast cancer and one to three positive lymph nodes with a recurrence score of 25 or lower, the addition of chemotherapy to endocrine therapy led to longer invasive disease-free survival and distant relapse-free survival compared to endocrine therapy alone. However, postmenopausal women with similar characteristics did not benefit from adjuvant chemotherapy in terms of invasive disease-free survival.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

Larissa A. Korde et al.

Summary: The guideline recommendations for neoadjuvant therapy for breast cancer suggest that patients should be managed by multidisciplinary teams and that appropriate candidates include those with inflammatory breast cancer or residual disease that may prompt a change in therapy.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR plus Breast Cancer-An NCDB Analysis (2004-2016)

Macy M. Goldbach et al.

Summary: The study found that short, moderate, and long durations of neoadjuvant endocrine therapy did not result in significant differences in pathologic response, with objective response rates of 56.7%, 52.1%, and 49.0% respectively. For patients with HR+ breast cancer, short-term neoadjuvant endocrine therapy may be a safe and effective way to delay surgery.

ANNALS OF SURGICAL ONCOLOGY (2021)

Add to Collection

Review Oncology

Clinical utility of the 21-gene assay in predicting response to neoadjuvant endocrine therapy in breast cancer: A systematic review and meta-analysis

M. G. Davey et al.

Summary: This study aimed to investigate the impact of OncotypeDX Recurrence Score (RS) on patients with ER+/ HER2- breast cancer undergoing neoadjuvant endocrine therapy (NET). The results showed that patients with low to intermediate RS were more likely to respond to NET, while those with high-risk RS were less likely to achieve partial response or conversion to breast conservation surgery.

BREAST (2021)

Add to Collection

Article Oncology

MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2--Advanced Breast Cancer

Patrick Neven et al.

Summary: Abemaciclib plus fulvestrant demonstrated significant improvements in PFS and OS compared to placebo plus fulvestrant in HR+, HER2(-) advanced breast cancer patients in both first- and second-line treatment subgroups. The benefits were particularly pronounced in patients with primary resistance to endocrine therapy and visceral disease.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer

Sara A. Hurvitz et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic

Mitch Dowsett et al.

NPJ BREAST CANCER (2020)

Add to Collection

Article Oncology

Molecular characterization of breast cancer needle core biopsy specimens by the 21-gene Breast Recurrence Score test

Debbie M. Jakubowski et al.

JOURNAL OF SURGICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

Stephen R. D. Johnston et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

J. A. Sparano et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay

Michaela Tsai et al.

JAMA ONCOLOGY (2018)

Add to Collection

Article Oncology

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

P. Cottu et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Article Oncology

Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study

Akiko Chiba et al.

ANNALS OF SURGICAL ONCOLOGY (2017)

Add to Collection

Article Oncology

Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial

Harry D. Bear et al.

JOURNAL OF SURGICAL ONCOLOGY (2017)

Add to Collection

Article Oncology

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer

Cynthia X. Ma et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection

Article Medicine, General & Internal

Palbociclib and Letrozole in Advanced Breast Cancer

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Review Oncology

Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer A Systematic Review and Meta-analysis

Laura M. Spring et al.

JAMA ONCOLOGY (2016)

Add to Collection

Article Oncology

Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients - A phase II trial

Duveken B. Y. Fontein et al.

EUROPEAN JOURNAL OF CANCER (2014)

Add to Collection

Meeting Abstract Oncology

Comparison of Oncotype DX® Recurrence Scores between Surgical and Core Biopsy Specimens in Breast Cancer Patients.

T. S. Stull et al.

CANCER RESEARCH (2011)

Add to Collection

Article Oncology

Molecular Characterization of Breast Cancer Core Biopsy Specimens by Gene Expression Analysis Using Standardized Quantitative RT-PCR.

J. Anderson et al.

CANCER RESEARCH (2010)

Add to Collection

Article Oncology

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer

Vladimir F. Semiglazov et al.

CANCER (2007)

Add to Collection

Article Oncology

Role of endocrine therapy in the neoadjuvant surgical setting

JM Dixon

ANNALS OF SURGICAL ONCOLOGY (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.